tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

PacBio price target lowered to $1.50 from $2 at Barclays

Barclays analyst Luke Sergott lowered the firm’s price target on PacBio (PACB) to $1.50 from $2 and keeps an Equal Weight rating on the shares. The shares ran up in early June following upbeat commentary at a conference, which creates a relatively higher bar for second half of 2025 numbers, the analyst tells investors in a research note. This makes Barclays more cautious given the “tough” National Institutes of Health funding environment.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1